newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

- GEM103 biological activity in intraocular compartment showed ability of potential first in class complement regulator to inhibit C3 activation and amplification - GEM103 continues to be well tolerated and intraocular pharmacokinetics support advanc